Prostate Cancer Treatment
Understand prostate cancer treatment options — active surveillance, radical prostatectomy, radiation, hormone therapy, and advanced therapies. Plan your care with Gaf Healthcare.
Estimated cost: $5,000 – $8,500 · Average stay: 4–6 days
Prostate cancer is the most common cancer in men in the Western world and the second most common cancer in men globally. Despite its high incidence, the majority of prostate cancers are slow-growing, confined to the prostate, and clinically manageable. The critical challenge in prostate cancer management is distinguishing indolent, low-risk disease — which may never require treatment and is safely managed by active surveillance — from intermediate- and high-risk disease that carries a meaningful risk of metastasis and death and warrants definitive treatment.
The prostate-specific antigen (PSA) blood test, combined with prostate biopsy and advanced imaging (multiparametric MRI of the prostate), forms the cornerstone of diagnosis and risk stratification. Prostate cancers are graded using the Gleason score / Grade Group system, which reflects the aggressiveness of the cancer cells under the microscope. Grade Group 1 (Gleason 6) represents low-risk, indolent disease; Grade Group 5 (Gleason 9–10) represents high-risk, potentially lethal disease.
Treatment for localised prostate cancer includes: active surveillance (for low-risk disease), radical prostatectomy (surgical removal of the prostate), external beam radiation therapy (EBRT) with or without brachytherapy, and focal therapy modalities (HIFU, cryotherapy). For locally advanced and metastatic disease, androgen deprivation therapy (ADT) — hormonal castration — combined with novel anti-androgen agents (abiraterone, enzalutamide, apalutamide) and chemotherapy (docetaxel) or PARP inhibitors (for BRCA-mutant disease) represent the current standard of care.
The decision between competing treatment modalities for localised prostate cancer requires nuanced discussion of the patient's age, life expectancy, risk group, individual priorities regarding side effect profiles (incontinence and erectile dysfunction risk varies between surgery and radiation), and the expertise available at the treating center.
Prostate Cancer Staging and Risk Stratification
Prostate cancer staging combines PSA level, clinical stage (based on digital rectal examination and MRI findings), and Gleason/Grade Group to classify men into risk groups that guide treatment recommendations:
Low-risk prostate cancer: PSA below 10 ng/mL, Grade Group 1 (Gleason 6), clinical stage T1–T2a. Disease is confined to the prostate with low risk of spread. Active surveillance — close monitoring without immediate treatment — is the guideline-recommended approach for suitable candidates, avoiding the side effects of treatment for a disease that may never require intervention.
Intermediate-risk: One or more of PSA 10–20, Grade Group 2–3, clinical stage T2b–T2c. Risk of extraprostatic extension and nodal involvement. Unfavourable intermediate-risk disease (Grade Group 3, multiple intermediate-risk factors) is treated more aggressively, often with radiation + short-course ADT.
High-risk and locally advanced: PSA >20, Grade Group 4–5, stage T3–T4, or pelvic lymph node involvement. High recurrence risk requiring aggressive multimodal treatment: surgery + adjuvant radiation, or long-course external beam radiation + brachytherapy boost + long-duration ADT.
Metastatic prostate cancer: Distant metastases — most commonly to bone, lymph nodes, and viscera. Historically managed with ADT alone; now treated with ADT + docetaxel chemotherapy or ADT + novel anti-androgen agents (abiraterone, enzalutamide, darolutamide), with dramatic improvement in overall survival from these combination strategies (STAMPEDE, LATITUDE, ENZAMET trials).
Who Is a Candidate for Prostate Cancer Treatment?
Candidacy for specific prostate cancer treatments is determined by disease risk group, patient age and life expectancy, PSA kinetics, MRI findings, and patient preferences regarding side effect profiles.
Active surveillance candidates: Men with low-risk prostate cancer (Grade Group 1, PSA <10, confined to prostate on MRI) and life expectancy below 10–15 years. Active surveillance requires PSA monitoring every 3–6 months, repeat MRI every 1–2 years, and repeat biopsy at 1–2 years. Men are moved to active treatment if their disease shows grade progression.
Radical prostatectomy candidates: Men with localised (T1–T3a) or locally advanced (T3b, selected cases) prostate cancer and life expectancy exceeding 10 years who prefer surgical treatment. Must have adequate cardiopulmonary reserve for general anaesthesia. Robotic-assisted radical prostatectomy (RARP) is the preferred approach at high-volume urological oncology centres — associated with lower blood loss, shorter hospital stay, and faster continence recovery than open surgery.
Radiation therapy candidates: Men across all risk groups who prefer radiation over surgery, or for whom surgery is medically inadvisable. External beam radiation (IMRT/VMAT) is combined with brachytherapy boost for high-risk disease and with ADT for intermediate- and high-risk groups. Radiation is also the standard salvage treatment for biochemical recurrence after radical prostatectomy.
Metastatic disease candidates: All men with hormone-naïve or castrate-resistant metastatic prostate cancer. Treatment selection depends on castration-sensitivity status, volume of metastatic disease, BRCA mutation status (for PARP inhibitor eligibility), and prior treatment history.
Prostate Cancer Treatment Modalities
Radical prostatectomy — surgical removal of the prostate gland and seminal vesicles with regional lymph node dissection — is the most commonly performed curative treatment for localised prostate cancer. Robotic-Assisted Radical Prostatectomy (RARP) using the da Vinci surgical system has become the dominant approach at high-volume centres: the robotic platform provides superior three-dimensional visualisation, instrument dexterity, and precision of nerve-sparing dissection compared to open or laparoscopic surgery. Bilateral nerve-sparing prostatectomy, when oncologically safe, preserves the neurovascular bundles responsible for erectile function, maximising post-operative potency recovery.
External beam radiation therapy — delivered using intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) — allows conformal dose delivery to the prostate and seminal vesicles while sparing surrounding structures (bladder, rectum). Typical regimens involve 20–28 fractions (moderately hypofractionated) or 5 fractions (stereotactic body radiation therapy / SBRT, the PACE-B trial confirming non-inferiority of 5-fraction SBRT to standard radiotherapy for low- and intermediate-risk prostate cancer). Low-dose-rate brachytherapy (LDR-BT) — permanent radioactive seed implantation — is an option for low- and favourable intermediate-risk disease.
Androgen Deprivation Therapy (ADT) — medical castration via LHRH agonists (goserelin, leuprolide) or antagonists (degarelix, relugolix) — reduces testosterone to castrate levels (<50 ng/dL), depriving prostate cancer cells of their growth signal. ADT is combined with radiation for intermediate- and high-risk localised disease, and is the foundation of metastatic treatment, now combined with docetaxel or novel anti-androgen agents in all suitable patients.
Procedure Steps
- Diagnosis and staging: PSA, digital rectal examination, multiparametric prostate MRI (mpMRI), systematic + targeted prostate biopsy guided by MRI findings; Gleason grading and Grade Group assignment.
- Metastatic staging (for intermediate- and high-risk): CT chest/abdomen/pelvis; bone scan; PSMA PET-CT (the gold standard staging tool for nodal and distant disease at PSA levels as low as 0.2 ng/mL).
- Risk stratification and multidisciplinary review; treatment decision made jointly by uro-oncologist and patient based on risk group, life expectancy, and preferences.
- For radical prostatectomy: robotic-assisted radical prostatectomy with bilateral pelvic lymph node dissection; bilateral or unilateral nerve-sparing according to oncological safety assessment.
- Pathological staging post-surgery; adjuvant radiation or ADT if high-risk pathological features (positive margins, pT3, node-positive).
- For radiation: definitive IMRT/VMAT ± brachytherapy boost ± concurrent and adjuvant ADT depending on risk group.
- PSA monitoring every 3–6 months post-treatment; PSMA PET-CT for PSA recurrence evaluation.
- For metastatic disease: castration initiation + docetaxel or novel anti-androgen agent as intensification from diagnosis.
Types of Prostate Cancer Treatment
Robotic-Assisted Radical Prostatectomy (RARP)
Surgical removal of the prostate through 5–6 small port incisions using the da Vinci robotic surgical system. Provides superior visualisation, tremor elimination, and instrument dexterity for nerve-sparing dissection. Hospital stay 1–2 days; catheter for 7–10 days; continence recovery over 3–12 months; erectile function recovery over 1–2 years (with nerve sparing). Preferred over open surgery at high-volume robotic prostatectomy programs.
Cost: $8,000 – $18,000
External Beam Radiation Therapy (IMRT/SBRT)
Radiation delivered from outside the body using a linear accelerator. IMRT (intensity-modulated) delivers conformal dose in 20–28 daily fractions over 4–6 weeks. SBRT delivers ablative doses in just 5 fractions over 1–2 weeks, providing equivalent tumour control for low- and intermediate-risk disease with dramatically reduced treatment duration. Typically combined with 6–36 months of ADT for high-risk disease.
Cost: $6,000 – $15,000 (full course)
High-Intensity Focused Ultrasound (HIFU) Focal Therapy
Ultrasound energy focused precisely to ablate a defined prostate region containing the tumour, leaving the remainder of the gland and surrounding structures intact. A focal therapy option for selected men with unilateral, intermediate-risk, MRI-visible localised prostate cancer who wish to minimise side effects. Lower risk of incontinence and erectile dysfunction than whole-gland treatments. Requires precise patient selection based on mpMRI and template mapping biopsy.
Cost: $9,000 – $18,000
Novel Hormone Therapy Intensification for Metastatic Disease
ADT combined with docetaxel chemotherapy, abiraterone (with prednisone), enzalutamide, apalutamide, or darolutamide — all of which have demonstrated significant overall survival improvements in landmark trials (STAMPEDE, LATITUDE, ARCHES, TITAN, ARASENS). Choice between agents is guided by patient comorbidities, drug interactions, and preference. PARP inhibitors (olaparib, rucaparib) are used for BRCA1/2-mutant castrate-resistant disease.
Cost: $1,000 – $6,000 per month (ongoing)
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
United States — $30,000 – $100,000 — Baseline
United Kingdom — $10,000 – $30,000 — ~70% vs. USA
Germany — $9,000 – $25,000 — ~73% vs. USA
India — $4,500 – $12,000 — Up to 88% vs. USA
UAE — $12,000 – $30,000 — ~68% vs. USA
Prostate cancer treatment costs vary widely depending on the modality chosen. Robotic prostatectomy is a one-time surgical expense. Radiation is a one-time course. However, for men with advanced or metastatic disease requiring ongoing hormonal therapy and novel anti-androgen agents, costs accumulate over years. Enzalutamide and abiraterone carry US monthly costs of $10,000–$15,000; biosimilar or generic equivalents approved by international regulatory agencies are available at internationally accredited centres at a fraction of this cost.
Gaf Healthcare provides transparent, itemised cost estimates for both the acute treatment episode and projected ongoing systemic therapy costs, enabling realistic long-term financial planning.
Recovery & Follow-up
Recovery from robotic prostatectomy is straightforward for most men: catheter for 7–10 days, light activity from week 1, driving from week 2–3, full activity by 4–6 weeks. Urinary incontinence — the most disruptive early side effect — typically resolves over 3–12 months with pelvic floor physiotherapy; the vast majority of men achieve social continence (0–1 pads per day) within 12 months of nerve-sparing surgery.
Erectile dysfunction after prostatectomy is common; the rate and degree of recovery depends on pre-operative potency, age, and whether bilateral nerve sparing was performed. A structured penile rehabilitation program (daily PDE5 inhibitor, vacuum erection device) started within weeks of surgery significantly improves long-term erectile recovery.
Radiation therapy side effects — urinary frequency, urgency, and bowel changes — typically peak during and shortly after treatment and resolve over 2–6 months. Long-term bladder and bowel effects are present in a minority of patients.
Recovery Tips
- Begin pelvic floor exercises (Kegel exercises) pre-operatively and restart immediately after catheter removal — they are the most effective intervention for continence recovery.
- Start penile rehabilitation program (daily tadalafil or sildenafil) within 4–6 weeks of surgery if nerve-sparing was performed; do not wait for spontaneous erections.
- For radiation patients: increase daily water intake; avoid caffeine and alcohol during treatment to reduce bladder irritation.
- Report any rectal bleeding, severe urinary retention, or signs of deep vein thrombosis after prostatectomy immediately.
- Maintain PSA monitoring every 3–6 months post-treatment — rising PSA detects recurrence early when salvage options are most effective.
- Manage ADT-related bone loss with calcium, vitamin D, and regular weight-bearing exercise; bone density scan annually.
- Address hot flushes from ADT with lifestyle measures and, if severe, low-dose medroxyprogesterone or cyproterone (discuss with your oncologist).
- Attend regular cardiovascular monitoring during ADT — long-term ADT increases metabolic syndrome and cardiovascular risk.
Risks & Complications
Radical prostatectomy risks include urinary incontinence (1–10% long-term total incontinence with experienced surgeon; up to 30% requiring ≥1 pad per day at 12 months), erectile dysfunction (varies from 30–90% depending on nerve-sparing, age, pre-operative function), bladder neck contracture, and rectal injury (rare). Operative mortality is below 0.5% at high-volume centres.
Radiation therapy risks include acute cystitis/proctitis during treatment, and long-term risks of radiation cystitis, proctitis, secondary malignancy (small but real risk), and urethral stricture. ADT risks include hot flushes, loss of libido, fatigue, osteoporosis (bone density loss requires monitoring and bisphosphonate/denosumab prophylaxis), cardiovascular risk, and cognitive effects.
Why GAF Healthcare
Prostate cancer treatment decisions involve nuanced risk-benefit analysis, competing modalities with similar oncological outcomes but different side effect profiles, and significant long-term medication management. Gaf Healthcare's urology oncology coordinators facilitate comprehensive second opinions from prostate cancer specialists, robotic prostatectomy program reviews, and transparent cost breakdowns for both the surgical or radiation episode and ongoing hormonal therapy. We connect patients with programs that have high robotic prostatectomy volumes — a critical predictor of continence and potency outcomes.
Frequently Asked Questions
Does prostate cancer always need treatment?
No — low-risk prostate cancer (Grade Group 1, PSA <10, clinically confined disease) has a very low risk of ever causing harm during a man's natural lifetime. Active surveillance — close monitoring with PSA, MRI, and repeat biopsy — is recommended by international guidelines for suitable candidates. Multiple large cohort studies confirm that men managed on active surveillance have equivalent cancer-specific survival to those treated immediately, while avoiding the side effects of treatment for years or decades.
Is robotic prostatectomy better than open surgery?
Robotic-assisted radical prostatectomy has largely replaced open retropubic prostatectomy at high-volume centres. Oncological outcomes (biochemical recurrence rates, surgical margin positivity) are equivalent between experienced robotic and open surgeons. Robotic surgery offers significantly less blood loss (virtually eliminating the need for transfusion), shorter catheter duration, shorter hospital stay, less post-operative pain, and equivalent or slightly faster continence recovery compared to open surgery.
What is PSMA PET-CT and why is it important?
PSMA (Prostate-Specific Membrane Antigen) PET-CT is a nuclear medicine imaging test that uses a radiolabelled PSMA-targeting molecule to detect prostate cancer deposits — including tiny nodal and bone metastases — at PSA levels as low as 0.2–0.5 ng/mL. It has dramatically improved the accuracy of staging for newly diagnosed high-risk prostate cancer and for detecting the site of recurrence after radical prostatectomy or radiation, enabling precise salvage targeting. PSMA PET-CT is now the gold standard staging and restaging tool for prostate cancer.
What is the difference between ADT, novel anti-androgens, and chemotherapy for advanced disease?
Androgen deprivation therapy (ADT — LHRH agonists or antagonists) reduces testosterone to castrate levels, depriving prostate cancer of its primary growth stimulus. However, ADT alone for metastatic disease is no longer the standard — all eligible men with newly diagnosed metastatic hormone-sensitive prostate cancer should receive ADT intensification with either docetaxel chemotherapy or a novel anti-androgen agent (abiraterone, enzalutamide, apalutamide, darolutamide). These combinations have extended median overall survival from approximately 34 months to 63+ months in the STAMPEDE trial.
How long does hormone therapy need to continue?
Duration of ADT for localised disease combined with radiation varies by risk group: 6 months for favourable intermediate-risk, 18–36 months for high-risk localised disease. For metastatic hormone-sensitive prostate cancer, ADT is continued indefinitely. When the cancer progresses despite castrate testosterone levels (castrate-resistant prostate cancer), treatment is switched to next-line agents (enzalutamide, abiraterone, cabazitaxel, PARP inhibitors) while continuing castration.
What is the risk of incontinence and erectile dysfunction after surgery?
Urinary incontinence after robotic prostatectomy is common in the early post-operative period; the vast majority of men regain social continence (0–1 daily pad) within 6–12 months, particularly with aggressive pelvic floor rehabilitation. Long-term total urinary incontinence requiring more than 2 pads daily occurs in approximately 3–8% of patients at experienced centres. Erectile dysfunction depends heavily on nerve-sparing, age, and pre-operative function. With bilateral nerve-sparing by an experienced surgeon in a man under 60 with good pre-operative potency, 60–80% recover functional erections (with or without PDE5 inhibitors) over 18–24 months.